Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
作者信息
Von Hoff D D, Green S J, Neidhart J A, Fabian C, Budd T, Boyd J F, Osborne C K
机构信息
University of Texas Health Science Center, San Antonio.
出版信息
Invest New Drugs. 1991 Feb;9(1):87-8. doi: 10.1007/BF00194553.
PMID:2026487
Abstract
摘要
相似文献
1
Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
Invest New Drugs. 1991 Feb;9(1):87-8. doi: 10.1007/BF00194553.
2
A phase II study of alanosine in advanced large bowel carcinoma.
Am J Clin Oncol. 1983 Apr;6(2):191-3. doi: 10.1097/00000421-198304000-00009.
3
Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma.
Am J Clin Oncol. 1984 Oct;7(5):543-4. doi: 10.1097/00000421-198410000-00030.
4
The treatment of acute leukemia with continuous infusion L-Alanosine.持续输注L-丙氨酸治疗急性白血病。
Invest New Drugs. 1983;1(3):249-51. doi: 10.1007/BF00208898.
5
Phase I study of L-alanosine (NSC 15353).
Cancer. 1983 Feb 1;51(3):378-80. doi: 10.1002/1097-0142(19830201)51:3<378::aid-cncr2820510303>3.0.co;2-i.
6
Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial.阿柔比星治疗晚期乳腺癌的II期评估：一项东南癌症研究组试验
Cancer Treat Rep. 1985 Sep;69(9):1029-30.
7
Phase II trial of acivicin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.阿西维辛治疗晚期乳腺癌的II期试验：一项癌症与白血病B组研究
Cancer Treat Rep. 1986 Oct;70(10):1247-8.
8
Phase I study of L-alanosine using a daily x 3 schedule.
Cancer Treat Rep. 1982 Jan;66(1):73-6.
9
Phase II evaluation of aclacinomycin-A (NSC-208734) in adenocarcinoma of the kidney.阿克拉霉素-A（NSC-208734）在肾癌中的II期评估。
Am J Clin Oncol. 1984 Oct;7(5):527-8. doi: 10.1097/00000421-198410000-00026.
10
Phase II clinical trial of acivicin in advanced breast cancer: an Eastern Cooperative Oncology Group Study.阿西维辛治疗晚期乳腺癌的II期临床试验：东部肿瘤协作组研究
Cancer Treat Rep. 1986 Oct;70(10):1237-8.
引用本文的文献
1
Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.针对缺乏甲基硫腺苷磷酸化酶（MTAP）活性的肿瘤：当前策略。
Cancer Biol Ther. 2011 Apr 1;11(7):627-32. doi: 10.4161/cbt.11.7.14948.
2
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.一项关于L-丙氨酸（一种腺嘌呤生物合成的强效抑制剂）在MTAP缺陷型癌症患者中的II期多中心研究。
Invest New Drugs. 2009 Feb;27(1):75-81. doi: 10.1007/s10637-008-9160-1. Epub 2008 Jul 11.
本文引用的文献
1
A phase II study of alanosine in advanced large bowel carcinoma.
Am J Clin Oncol. 1983 Apr;6(2):191-3. doi: 10.1097/00000421-198304000-00009.
2
The treatment of acute leukemia with continuous infusion L-Alanosine.持续输注L-丙氨酸治疗急性白血病。
Invest New Drugs. 1983;1(3):249-51. doi: 10.1007/BF00208898.
3
Phase II clinical trial of L-alanosine in advanced upper aerodigestive cancer.L-丙氨酰谷氨酰胺用于晚期上消化道癌症的II期临床试验。
Cancer Treat Rep. 1983 Nov;67(11):1047.
4
Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma.
Am J Clin Oncol. 1984 Oct;7(5):543-4. doi: 10.1097/00000421-198410000-00030.
5
Alanosine, a new antiviral and antitumour agent isolated from a Streptomyces.阿拉诺新，一种从链霉菌中分离出的新型抗病毒和抗肿瘤药物。
Nature. 1966 Sep 10;211(5054):1198-9. doi: 10.1038/2111198a0.
Zotero 插件